Literature DB >> 27314101

ATRX mutations and glioblastoma: Impaired DNA damage repair, alternative lengthening of telomeres, and genetic instability.

Carl Koschmann1, Pedro R Lowenstein2, Maria G Castro2.   

Abstract

Alpha thalassemia/mental retardation syndrome X-linked (ATRX) is mutated in nearly a third of pediatric glioblastoma (GBM) patients. We developed an animal model of ATRX-deficient GBM. Using this model combined with analysis of multiple human glioma genome-wide datasets, we determined that ATRX mutation leads to genetic instability, impaired non-homologous end joining, and alternate lengthening of telomeres (ALT).

Entities:  

Keywords:  Chromatin; NHEJ; histone mutations; homologous recombination; pediatric GBM

Year:  2016        PMID： 27314101      PMCID： PMC4909411          DOI： 10.1080/23723556.2016.1167158

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies.

Authors:  Yutong Xue; Richard Gibbons; Zhijiang Yan; Dafeng Yang; Tarra L McDowell; Salvatore Sechi; Jun Qin; Sharleen Zhou; Doug Higgs; Weidong Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-02       Impact factor: 11.205

2.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.

Authors:  Jeremy Schwartzentruber; Andrey Korshunov; Xiao-Yang Liu; David T W Jones; Elke Pfaff; Karine Jacob; Dominik Sturm; Adam M Fontebasso; Dong-Anh Khuong Quang; Martje Tönjes; Volker Hovestadt; Steffen Albrecht; Marcel Kool; Andre Nantel; Carolin Konermann; Anders Lindroth; Natalie Jäger; Tobias Rausch; Marina Ryzhova; Jan O Korbel; Thomas Hielscher; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Martin Ebinger; Martin U Schuhmann; Wolfram Scheurlen; Arnulf Pekrun; Michael C Frühwald; Wolfgang Roggendorf; Christoph Kramm; Matthias Dürken; Jeffrey Atkinson; Pierre Lepage; Alexandre Montpetit; Magdalena Zakrzewska; Krzystof Zakrzewski; Pawel P Liberski; Zhifeng Dong; Peter Siegel; Andreas E Kulozik; Marc Zapatka; Abhijit Guha; David Malkin; Jörg Felsberg; Guido Reifenberger; Andreas von Deimling; Koichi Ichimura; V Peter Collins; Hendrik Witt; Till Milde; Olaf Witt; Cindy Zhang; Pedro Castelo-Branco; Peter Lichter; Damien Faury; Uri Tabori; Christoph Plass; Jacek Majewski; Stefan M Pfister; Nada Jabado
Journal:  Nature       Date:  2012-01-29       Impact factor: 49.962

3.  Mutational landscape and clonal architecture in grade II and III gliomas.

Authors:  Hiromichi Suzuki; Kosuke Aoki; Kenichi Chiba; Yusuke Sato; Yusuke Shiozawa; Yuichi Shiraishi; Teppei Shimamura; Atsushi Niida; Kazuya Motomura; Fumiharu Ohka; Takashi Yamamoto; Kuniaki Tanahashi; Melissa Ranjit; Toshihiko Wakabayashi; Tetsuichi Yoshizato; Keisuke Kataoka; Kenichi Yoshida; Yasunobu Nagata; Aiko Sato-Otsubo; Hiroko Tanaka; Masashi Sanada; Yutaka Kondo; Hideo Nakamura; Masahiro Mizoguchi; Tatsuya Abe; Yoshihiro Muragaki; Reiko Watanabe; Ichiro Ito; Satoru Miyano; Atsushi Natsume; Seishi Ogawa
Journal:  Nat Genet       Date:  2015-04-13       Impact factor: 38.330

4.  Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.

Authors:  Rachel Litman Flynn; Kelli E Cox; Maya Jeitany; Hiroaki Wakimoto; Alysia R Bryll; Neil J Ganem; Francesca Bersani; Jose R Pineda; Mario L Suvà; Cyril H Benes; Daniel A Haber; Francois D Boussin; Lee Zou
Journal:  Science       Date:  2015-01-16       Impact factor: 47.728

5.  Alpha thalassemia/mental retardation syndrome X-linked gene product ATRX is required for proper replication restart and cellular resistance to replication stress.

Authors:  Justin Wai-Chung Leung; Gargi Ghosal; Wenqi Wang; Xi Shen; Jiadong Wang; Lei Li; Junjie Chen
Journal:  J Biol Chem       Date:  2013-01-16       Impact factor: 5.157

6.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

7.  ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.

Authors:  Carl Koschmann; Anda-Alexandra Calinescu; Felipe J Nunez; Alan Mackay; Janet Fazal-Salom; Daniel Thomas; Flor Mendez; Neha Kamran; Marta Dzaman; Lakshman Mulpuri; Johnathon Krasinkiewicz; Robert Doherty; Rosemary Lemons; Jacqueline A Brosnan-Cashman; Youping Li; Soyeon Roh; Lili Zhao; Henry Appelman; David Ferguson; Vera Gorbunova; Alan Meeker; Chris Jones; Pedro R Lowenstein; Maria G Castro
Journal:  Sci Transl Med       Date:  2016-03-02       Impact factor: 17.956

Review 8.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.

Authors:  Monika E Hegi; Lili Liu; James G Herman; Roger Stupp; Wolfgang Wick; Michael Weller; Minesh P Mehta; Mark R Gilbert
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

Review 9.  Is non-homologous end-joining really an inherently error-prone process?

Authors:  Mireille Bétermier; Pascale Bertrand; Bernard S Lopez
Journal:  PLoS Genet       Date:  2014-01-16       Impact factor: 5.917

10.  Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.

Authors:  Yuchen Jiao; Patrick J Killela; Zachary J Reitman; Ahmed B Rasheed; Christopher M Heaphy; Roeland F de Wilde; Fausto J Rodriguez; Sergio Rosemberg; Sueli Mieko Oba-Shinjo; Suely Kazue Nagahashi Marie; Chetan Bettegowda; Nishant Agrawal; Eric Lipp; Christopher Pirozzi; Giselle Lopez; Yiping He; Henry Friedman; Allan H Friedman; Gregory J Riggins; Matthias Holdhoff; Peter Burger; Roger McLendon; Darell D Bigner; Bert Vogelstein; Alan K Meeker; Kenneth W Kinzler; Nickolas Papadopoulos; Luis A Diaz; Hai Yan
Journal:  Oncotarget       Date:  2012-07
  10 in total
  22 in total

Review 1.  Mutant ATRX: uncovering a new therapeutic target for glioma.

Authors:  Santiago Haase; María Belén Garcia-Fabiani; Stephen Carney; David Altshuler; Felipe J Núñez; Flor M Méndez; Fernando Núñez; Pedro R Lowenstein; Maria G Castro
Journal:  Expert Opin Ther Targets       Date:  2018-06-20       Impact factor: 6.902

Review 2.  Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease.

Authors:  Flor M Mendez; Felipe J Núñez; Maria B Garcia-Fabiani; Santiago Haase; Stephen Carney; Jessica C Gauss; Oren J Becher; Pedro R Lowenstein; Maria G Castro
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300

3.  Key rates for the grades and transformation ability of glioma: model simulations and clinical cases.

Authors:  Elizabeth Scribner; James R Hackney; Hannah C Machemehl; Reina Afiouni; Krishna R Patel; Hassan M Fathallah-Shaykh
Journal:  J Neurooncol       Date:  2017-04-27       Impact factor: 4.130

4.  ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization.

Authors:  Tingting Qin; Brendan Mullan; Ramya Ravindran; Dana Messinger; Ruby Siada; Jessica R Cummings; Micah Harris; Ashwath Muruganand; Kalyani Pyaram; Zachary Miklja; Mary Reiber; Taylor Garcia; Dustin Tran; Carla Danussi; Jacqueline Brosnan-Cashman; Drew Pratt; Xinyi Zhao; Alnawaz Rehemtulla; Maureen A Sartor; Sriram Venneti; Alan K Meeker; Jason T Huse; Meredith A Morgan; Pedro R Lowenstein; Maria G Castro; Viveka Nand Yadav; Carl Koschmann
Journal:  Cell Rep       Date:  2022-01-11       Impact factor: 9.995

5.  Tumor Copy Number Deconvolution Integrating Bulk and Single-Cell Sequencing Data.

Authors:  Haoyun Lei; Bochuan Lyu; E Michael Gertz; Alejandro A Schäffer; Xulian Shi; Kui Wu; Guibo Li; Liqin Xu; Yong Hou; Michael Dean; Russell Schwartz
Journal:  J Comput Biol       Date:  2020-03-16       Impact factor: 1.479

Review 6.  Alpha Thalassemia/Mental Retardation Syndrome X-Linked, the Alternative Lengthening of Telomere Phenotype, and Gliomagenesis: Current Understandings and Future Potential.

Authors:  Jenny He; Alireza Mansouri; Sunit Das
Journal:  Front Oncol       Date:  2018-01-08       Impact factor: 6.244

7.  Level of FACT defines the transcriptional landscape and aggressive phenotype of breast cancer cells.

Authors:  Daria Fleyshman; Laura Prendergast; Alfiya Safina; Geraldine Paszkiewicz; Mairead Commane; Kelsey Morgan; Kristopher Attwood; Katerina Gurova
Journal:  Oncotarget       Date:  2017-03-28

8.  Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST.

Authors:  Hsiang-Chih Lu; Vanessa Eulo; Anthony J Apicelli; Melike Pekmezci; Yu Tao; Jingqin Luo; Angela C Hirbe; Sonika Dahiya
Journal:  Oncotarget       Date:  2018-05-01

Review 9.  Combination therapy to checkmate Glioblastoma: clinical challenges and advances.

Authors:  Debarati Ghosh; Saikat Nandi; Sonali Bhattacharjee
Journal:  Clin Transl Med       Date:  2018-10-16

Review 10.  Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.

Authors:  Maria B Garcia-Fabiani; Santiago Haase; Andrea Comba; Stephen Carney; Brandon McClellan; Kaushik Banerjee; Mahmoud S Alghamri; Faisal Syed; Padma Kadiyala; Felipe J Nunez; Marianela Candolfi; Antonela Asad; Nazareno Gonzalez; Marisa E Aikins; Anna Schwendeman; James J Moon; Pedro R Lowenstein; Maria G Castro
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 5.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.